Intravenous placebo
Phase 3
Intravenous placebo is one of 31 therapeutic programs targeting Delirium. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
167 competitors in Delirium
#DrugCompanyPhaseTrials
1Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Victoza
Novo NordiskPhase 3
Intuniv
PPromius Pharma, LLC
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Sodiumchloride
RRadboud University Medical Center
Phase 3
Intravenous placebo
WWake Forest University Health Sciences
Phase 3
Rozerem
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Intravenous placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]